329 related articles for article (PubMed ID: 3486090)
1. Parkinson's disease.
Lieberman AN
Compr Ther; 1986 Mar; 12(3):25-9. PubMed ID: 3486090
[No Abstract] [Full Text] [Related]
2. Parkinson's disease in 1984: an update.
Lang AE; Blair RD
Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779
[TBL] [Abstract][Full Text] [Related]
3. [Therapy of Parkinson's disease. Practical criteria of treatment].
Casacchia M; Carolei A; Zamponi A; Agnoli A; Fazio C
Recenti Prog Med; 1976 May; 60(5):567-84. PubMed ID: 14360
[No Abstract] [Full Text] [Related]
4. MAO type B inhibitors as adjunct to L-dopa therapy.
Youdim MB; Finberg JP
Adv Neurol; 1987; 45():127-36. PubMed ID: 3103383
[No Abstract] [Full Text] [Related]
5. [Therapy of Parkinson's syndrome].
Clemens R
Dtsch Med Wochenschr; 1976 Mar; 101(11):420-3. PubMed ID: 767084
[No Abstract] [Full Text] [Related]
6. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
Tetrud JW; Langston JW
J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
[TBL] [Abstract][Full Text] [Related]
7. [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
Chen S
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):50-2, 64. PubMed ID: 1591961
[TBL] [Abstract][Full Text] [Related]
8. The drug treatment of Parkinson's disease.
Morris JG
Aust Fam Physician; 1984 May; 13(5 Suppl):6-8, 11. PubMed ID: 6497767
[TBL] [Abstract][Full Text] [Related]
9. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy: problems and practices.
Muenter MD
Clin Neuropharmacol; 1986; 9 Suppl 1():S23-36. PubMed ID: 3708606
[TBL] [Abstract][Full Text] [Related]
11. R-(-)-deprenyl and parkinsonism.
Yahr MD
J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
[TBL] [Abstract][Full Text] [Related]
12. New and emerging strategies for improving levodopa treatment.
Tolosa ES; Valldeoriola F; Martí MJ
Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259
[TBL] [Abstract][Full Text] [Related]
13. Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
Doudet D; Gross C; Lebrun-Grandie P; Bioulac B
Electromyogr Clin Neurophysiol; 1986 Dec; 26(8):711-27. PubMed ID: 3493894
[No Abstract] [Full Text] [Related]
14. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
15. How to achieve maximum benefit for the patient with Parkinson's disease.
Greer M
Geriatrics; 1976 Apr; 31(4):89-96. PubMed ID: 4356
[No Abstract] [Full Text] [Related]
16. Parkinson's disease: recent advances in therapy.
Jankovic J
South Med J; 1988 Aug; 81(8):1021-7. PubMed ID: 3043683
[No Abstract] [Full Text] [Related]
17. [Antiparkinsonian drugs (author's transl)].
Ando K
No To Shinkei; 1980 Aug; 32(8):743-53. PubMed ID: 7008813
[No Abstract] [Full Text] [Related]
18. Recent developments in the treatment of Parkinson's disease.
Greer M
Geriatrics; 1985 Feb; 40(2):34-8, 41. PubMed ID: 2857148
[TBL] [Abstract][Full Text] [Related]
19. MPTP: clinical implications.
Stern G
J Neural Transm Suppl; 1986; 20():77-81. PubMed ID: 3091763
[TBL] [Abstract][Full Text] [Related]
20. [Decarboxylase inhibitors combined with L-dopa in the treatment of Parkinson's disease].
Rondot P
Rev Prat; 1974 Mar; 24(15):1211-2, 1215-6, 1219. PubMed ID: 4416964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
